A battery of computer-based psychological tests given to seven patients with chronic hepatic encephalopathy showed them to be intellectually impaired, particularly on speed-based measures, as compared with general hospital patients and with patients with cirrhosis but without clinical or electroencephalographic evidence of encephalopathy. Two of the seven patients in the latter group also showed evidence of cognitive impairment on some tests. The effects of levodopa were also evaluated by sequential assessment with these tests. Although there was some improvement in speed of performance on certain tasks and a suggestion of deterioration on other measures, there was little overall change. It is concluded that levodopa has an 'arousing' or antidepressant action and that its effect on intellectual functions is secondary to this alerting effect and is consequently dependent on the emotional and attentional status of the patient.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC492074 | PMC |
| http://dx.doi.org/10.1136/jnnp.38.8.794 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Ketogenesis supports hepatic polyunsaturated fatty acid homeostasis via fatty acid elongation.
Sci Adv
January 2025
Division of Molecular Medicine, Department of Medicine, University of Minnesota Medical School, Minneapolis, MN, USA.
Ketogenesis is a dynamic metabolic conduit supporting hepatic fat oxidation particularly when carbohydrates are in short supply. Ketone bodies may be recycled into anabolic substrates, but a physiological role for this process has not been identified. Here, we use mass spectrometry-based C-isotope tracing and shotgun lipidomics to establish a link between hepatic ketogenesis and lipid anabolism.
View Article and Find Full Text PDFAdipokines regulate the development and progression of MASLD through organellar oxidative stress.
Hepatol Commun
February 2025
Central laboratory, Endocrine and Metabolic Diseases Hospital of Shandong First Medical University, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, Shandong, China.
The prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD), which is increasingly being recognized as a leading cause of chronic liver pathology globally, is increasing. The pathophysiological underpinnings of its progression, which is currently under active investigation, involve oxidative stress. Human adipose tissue, an integral endocrine organ, secretes an array of adipokines that are modulated by dietary patterns and lifestyle choices.
View Article and Find Full Text PDFMulti-target regulatory effects of rhaponticin in a rat model of hepatic fibrosis revealed by non-targeted metabolomics.
Front Pharmacol
January 2025
School of Pharmacy, Guizhou University of Traditional Chinese Medicine, Guiyang, China.
Introduction: Hepatic fibrosis (HF), a progressive chronic liver disease, is a serious threat to global public health. The lack of preventive and therapeutic strategies has created an urgent need for effective anti-fibrosis agents. There is growing evidence that natural products might provide safe and effective interventions for HF.
View Article and Find Full Text PDFNedosiran in pediatric patients with PH1 and relatively preserved kidney function, a phase 2 study (PHYOX8).
Pediatr Nephrol
January 2025
Novo Nordisk A/S, Lexington, MA, USA.
Background: Primary hyperoxaluria type 1 (PH1) is an autosomal recessive disorder with dysregulated glyoxylate metabolism in the liver. Oxalate over-production leads to renal stones, progressive kidney damage and renal failure, with potentially life-threatening systemic oxalosis. Nedosiran is a synthetic RNA interference therapy, designed to reduce hepatic lactate dehydrogenase (LDH) to decrease oxalate burden in PH.
View Article and Find Full Text PDFNovel bioactive peptides alleviate Western diet-induced MAFLD in C57BL/6J mice by inhibiting NLRP3 inflammasome activation and pyroptosis via TLR4/NF-κB and Keap1/Nrf2/HO-1 signaling pathways.
Int Immunopharmacol
January 2025
Department of Animal Science and Biotechnology, Tunghai University, Taichung 407224 Taiwan. Electronic address:
Metabolic-associated fatty liver disease (MAFLD) has emerged as a leading chronic liver disease. This condition is characterized by an abnormal accumulation of fat within liver and can progress from simple steatosis to more severe stages involving chronic inflammation and oxidative stress. In this study, we investigated the potential therapeutic effects and underlying mechanism of novel bioactive peptides (EWYF and EWFY) on Western diet-induced MAFLD in C57BL/6J mice.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!